Vaxart Scores IND For S-Only Oral Tablet COVID-19 Vaccine Candidate

The U.S. Food and Drug Administration (FDA) has approved the continued development of a new oral tablet SARS-CoV-2 vaccine candidate. The drug, created by Vaxart, completed its Phase I trial and has submitted an Investigational New Drug application to move forward.